MC
FOLD

Maverick Capital’s Amicus Therapeutics FOLD Stock Holding History

Maverick Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,522
Closed -$82K – 694
2021
Q2 		$82K Sell
8,522
-4,254
-33% -$41.5K ﹤0.01% 579
2021
Q1 		$126K Buy
+12,776
New +$198K ﹤0.01% 556

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital's FOLD Position: Q3 2021 in Review

Maverick Capital sold out of Amicus Therapeutics (FOLD) in Q3 2021, closing a stake of 8,522 shares — an estimated $82K sold.

Maverick Capital first reported a position in FOLD in Q1 2021 and held it in 2 quarters. The position peaked at $126K in Q1 2021. 237 funds tracked by Wall St. Rank hold FOLD as of Q3 2021.

  • Maverick Capital reported no remaining Amicus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Maverick Capital sold 8,522 Amicus Therapeutics shares in Q3 2021, an estimated $82K.
  • Maverick Capital first reported a position in Amicus Therapeutics in Q1 2021 and held it in 2 quarters.
  • Maverick Capital's Amicus Therapeutics position peaked at $126K in Q1 2021.
  • 237 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.